Trade Summary

3 months ago, Martell Ron, serving as Pres, CEO at Jasper Therapeutics, Inc. (JSPR), purchased 41,000 shares at $2.43 per share, for a total transaction value of $99,630.00. Following this transaction, Martell Ron now holds 74,118 shares of JSPR.

This purchase represents a 124.00% increase in Martell Ron's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, September 22, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, September 24, 2025, 2 days after the trade was made.

Jasper Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.